In a bold bid to dominate the neuropsychiatric treatment space, Supernus Pharmaceuticals Inc. announced Monday that it will acquire Sage Therapeutics Inc. in a transaction valued at up to $795 million, striking a deal that could reshape the pharmaceutical landscape in central nervous system (CNS) care.

Backed by Saul Ewing LLP, Supernus will pay $8.50 per share in cash—a total of $561 million—to purchase Sage, based in Cambridge, Massachusetts. But the real intrigue lies in the additional contingent value rights (CVRs), which could boost the final payout to $12 per share if future performance benchmarks are hit.

The Crown Jewel: Zurzuvae Enters Supernus’ Arsenal

A major coup in this acquisition is Zurzuvae, the first and only FDA-approved oral therapy for postpartum depression. The blockbuster drug is expected to help Supernus trim up to $200 million in annual costs while supercharging its CNS pipeline.

“This acquisition is a game-changer,” said Jack Khattar, CEO of Supernus. “Zurzuvae is a novel, differentiated treatment that fits perfectly into our growth trajectory and long-term CNS strategy.”

Supernus said the acquisition adds a fourth growth pillar to its portfolio, further diversifying revenue streams and cementing its commitment to novel psychiatric and neurological therapies.

Strategic Pivot or Surrender? Sage’s Next Chapter

For Sage Therapeutics, represented by Kirkland & Ellis LLP, the deal marks the end of a strategic soul-searching journey.

“We’ve built something meaningful,” said CEO Barry Greene of Sage. “From discovery to FDA approval, Zurzuvae is a testament to our team’s dedication. We believe this transaction delivers significant value to shareholders and ensures the continued success of our innovations.”

The CVR agreement includes performance-based incentives:

• $1.00/share if Zurzuvae hits $375 million in U.S. sales by 2030

• $0.50/share if the drug is commercially launched in Japan

Financing, Timeline, and Legal Muscle

Supernus plans to fully fund the acquisition through existing cash reserves, signaling strong internal liquidity. The transaction, approved by the boards of both companies, is slated to close in Q3 2025, pending regulatory approval and completion of a tender offer.

Kirkland & Ellis’ legal team, including partners Graham Robinson, Laura Knoll, and Merric Kaufman, is guiding Sage through the acquisition. Supernus’ counsel from Saul Ewing LLP is steering the buyer’s end of the transaction.